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Varese, Salerno, Mestre, Naples, Benevento, Florence, Potenza, Messina, Terni, and Pordenone, ItalyOBJECTIVES The purpose of this study was to determine clinical and echocardiographic correlates of
acute heart failure, cardiogenic shock and in-hospital mortality in a large cohort of tako-tsubo cardiomy-
opathy (TTC) patients.
BACKGROUND Despite good long-term prognosis, life-threatening complications due to hemody-
namic instability can occur early in TTC patients.
METHODS The study population consisted of 227 patients (66.2  12.2 years of age; females, 90.3%)
enrolled in the Tako-tsubo Italian Network, undergoing transthoracic two-dimensional echocardiography
on admission and at short-term follow-up (4.3 [4 to 6] weeks). Patients were divided into two groups
according to the presence or absence of major adverse events, a composite of acute heart failure, cardio-
genic shock, and in-hospital mortality.
RESULTS Major adverse events occurred in 59 patients (25.9%). The variables for elderly patients$75
years of age (42.4% vs. 23.8%; p¼ 0.011): left ventricular (LV) ejection fraction (35.1 5.9% vs. 38.4 4.6%,
p < 0.001), wall motion score index (1.9  0.2 vs. 1.7  0.2, p < 0.001), E/e0 ratio (13.5  4.3 vs. 9.9  3.3
[where E/e0 is ratio of mitral E peak velocity and averaged e0 velocity], p< 0.001), LV outﬂow tract obstruc-
tion (23.7 vs. 8.9%, p ¼ 0.006), pulmonary artery systolic pressure (47.4  12.3 mm Hg vs. 38.0  9.2 mm
Hg; p< 0.001), right ventricular involvement (28.8 vs. 9.5%; p< 0.001), and reversible moderate-to-severe
mitral regurgitation (49.1 vs. 11.9%; p < 0.001), were signiﬁcantly different between groups and were
associated with adverse events. At multivariate analysis, LV ejection fraction (HR: 0.92; 95% CI: 0.89 to
0.95; p < 0.001), E/e0 ratio (HR: 1.13; 95% CI: 1.02 to 1.24; p ¼ 0.011), reversible moderate to severe mitral
regurgitation (HR: 3.25; 95% CI: 1.16 to 9.10; p ¼ 0.025), and age$75 years (HR: 2.81; 95% CI: 1.05 to 7.52;
p ¼ 0.039) were independent correlates of major adverse events.
CONCLUSIONS Echocardiographic parameters provide additional information compared to other
variables routinely used in clinical practice to identify patients at higher risk of hemodynamic deteriora-
tion and poor in-hospital outcome, allowing prompt institution of appropriate pharmacological treatment
and adequate mechanical support. (J Am Coll Cardiol Img 2014;7:119–29) ª 2014 by the American
College of Cardiology Foundation
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120ako-tsubo cardiomyopathy (TTC) is typically
characterized by transient left ventricular (LV)
systolic dysfunction with morphological fea-
tures of apical ballooning, although other
variant forms (e.g., midventricular ballooning) have
also been described (1–3). It occurs most often in
post-menopausal women and is usually triggered by
emotional or physical stress, with complete recovery
of LV systolic function within a few days or weeks
(4,5). Despite its favorable long-term prognosis
and very low mortality, TTC is not considered a
benign condition, because of the occurrence ofFrom the *D
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tﬂow
indexlife-threatening complications during the
acute phase, related to hemodynamic
instability (e.g., acute heart failure, cardio-
genic shock) in a substantial proportion of
patients (6–8). Owing to its widespread use
in critical care settings, echocardiography
has become the noninvasive imaging mo-
dality of choice for assessing TTC (2,9).
However, the combination of clinical,
electrocardiographic (ECG), laboratory,
and echocardiographic measures routinely
used in clinical practice for TTC patients
experiencing major adverse events due to
hemodynamic instability have not yet been
well described. The aim of this study was to
identify the clinical and echocardiographic
determinants of major adverse events, a
composite of acute heart failure, cardio-
genic shock, and in-hospital mortality, in a
large cohort of TTC patients.METHODS
Study population. The study population consisted of
227 patients enrolled in the Tako-Tsubo Italian
Network, undergoing comprehensive transthoracic
2-dimensional echocardiography on admission and
at short-term follow-up (4.3 [4 to 6] weeks) (8,10).epartment of Heart Sciences, Circolo Hospital and Macchi
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tient demographics (sex, age, heart rate, systolic and
diastolic blood pressure), signs and symptoms at
presentation, medical history, trigger events, ECG
ST-segment changes and presence of prolonged
QTc interval on admission, and clinical observations
during hospitalization (including major cardiac
events). Emotional or physical triggers were identi-
ﬁed as previously described (8). Venous blood was
collected every 3 hours to measure troponin I con-
centration in the acute phase, and collection
continued until a peak value was observed. All
patients underwent coronary angiography and left
ventriculography within 24 hours of symptom onset.
Deﬁnition of major adverse events due to hemody-
namic instability. Major adverse events were deﬁned
as a composite of acute heart failure, cardiogenic
shock, and in-hospital mortality. In particular:
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pulmonary edema, dyspnea, and/or oxygen desa-
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121 In-hospital mortality was deﬁned as cardiac death
or death from any cause.
Echocardiography. All echocardiographic examina-
tions were performed within 6 hours of hospital
admission, before coronary angiography, and were
repeated at 5  1.6 (range 4 to 6) weeks after
symptom onset. A commercially available cardiac
ultrasonography system with a 2.5 to 4.5-MHz
phased-array transducer with second harmonic
capability was used for complete 2-dimensional
Doppler echocardiography. All examinations were
performed by observers blinded to clinical data.
LV regional wall motion abnormalities and presence
of typical circular systolic dysfunction with
involvement of $4 coronary territories were evalu-
ated by visual assessment of multiple apical and
short-axis views, as previously described (9). All
echocardiographic images were digitally recorded
and reviewed by 2 expert readers (R.C. and F.R.).
Three cardiac cycles from the apical 4- and 2-
chamber views and the parasternal short-axis view
at the level of the mitral valve and papillary muscles
were stored in cine-loop format for off-line analysis.
LV ejection fraction (EF) was calculated using
biplane Simpson’s rule from the apical 4- and 2-
chamber views (11). Left atrial (LA) volume was
assessed by the biplane area-length method and
indexed to body surface area (11). Right ventricular
(RV) wall motion was evaluated by visual assessment
for the detection of RV involvement (12). The echo
transducer was adjusted to the level of the RV
chamber to achieve optimal visualization of RV size
and RV endocardial borders. Tricuspid annular
plane systolic excursion (TAPSE) was calculated as
previously described (13). LV diastolic function was
evaluated according to American Society of Echo-
cardiography recommendations (14). Early (e0)
diastolic tissue Doppler velocities were measured at
the septal and lateral corners of the mitral annulus,
and the mean between the two values was calculated.
The ratio of mitral E peak velocity and averaged e0
velocity (E/e0) was calculated. Mitral regurgitation
(MR) was quantiﬁed from color Doppler imaging
and semiquantitatively graded as absent, minimal
(within normal limits), mild, moderate, or severe,
using standardized criteria (15). Moderate MR was
conﬁrmed by vena contracta measurement (3 to 7
mm) (16). Reversible signiﬁcant MR was deﬁned as
reversible moderate to severe MR detected during
the ﬁrst echocardiographic evaluation that dis-
appeared at follow-up examination. LV outﬂow
tract obstruction (LVOTO) was detected by
continuous wave Doppler. Using the modiﬁed
Bernoulli equation, a cut-off value of 25 mm Hg fordynamic intraventricular pressure gradient was
considered signiﬁcant LVOTO (17). With contin-
uous wave Doppler echocardiography, peak
tricuspid regurgitant velocity recorded from any
view was used to determine pulmonary artery sys-
tolic pressure (sPAP) with the simpliﬁed Bernoulli
equation [sPAP ¼ 4 (peak velocity)2 þ mean right
atrial pressure]; mean right atrial pressure was esti-
mated as previously described (18).
Statistical analysis. Statistical analyses included
descriptive statistics (frequency and percentage of
categorical variables, mean  SD of continuous
normally distributed variables, and median values
and an interquartile range of continuous non-
normally distributed variables). The normal distri-
bution of continuous variables was veriﬁed with the
Kolmogorov-Smirnov goodness-of-ﬁt test. Con-
tinuous variables were then compared by using an
independent sample Student t test or Mann-
Whitney U test, and categorical variables were
compared with chi-square statistics or a Fisher exact
test, when appropriate. The associations of selected
variables with major adverse events were assessed
with Cox proportional hazard models using uni-
variate and stepwise multivariate procedures. A
signiﬁcance of 0.05 was required for a variable to be
included in the multivariate model, whereas 0.1 was
the cut-off value for exclusion. Hazard ratios (HR)
with 95% conﬁdence intervals (CIs) were estimated.
The following covariates were analyzed: age $75
years, heart rate, chest pain with dyspnea, brain
natriuretic peptide (BNP), LVEF, E/e0 ratio, sPAP,
moderate to severe MR, RV involvement, and
LVOTO. TheHosmer-Lemeshow statistic was used
to assess the goodness-of-ﬁt of the logistic regression
model. A p value <0.05 was considered statistically
signiﬁcant. In addition, to investigate the incre-
mental prognostic value of echocardiographic corre-
lates of major adverse events compared with clinical,
we conducted interactive stepwise procedures with
ECG and laboratory ﬁndings. Therefore, clinical
data (including age, sex, presenting symptoms, blood
pressure, heart rate) were ﬁrst analyzed and the global
chi-square value was calculated. Subsequent steps
were created after adding ECG changes at admis-
sion, laboratory ﬁndings (troponin I, CK-MB, and
BNP peak) and independent echocardiographic
correlates of major adverse events (moderate to
severe MR, E/e0 ratio, and EF). The incremental
prognostic value of the added variables was deter-
mined by comparison of the global chi-square value
calculated at each step. The chi-square of the model
was calculated from the log likelihood ratio. A sta-
tistically signiﬁcant increase in global chi-square
Table 1. Clinical and Demographic Characteristics of the Study Population
Overall
Population
(n [ 227)
Patients With
Major
Complications
(n [ 59)
Patients Without
Major
Complications
(n [ 168) p Value
Age, yrs 66.2  12.2 67.5  14.5 65.8  11.4 0.372
Age $ 75 yrs 65 (28.6) 25 (42.4) 40 (23.8) 0.011
Female 205 (90.3) 54 (91.5) 151 (89.9) 0.804
Body surface area, m2 1.6  0.1 1.6  0.1 1.6  0.1 0.054
Medical history
Hypertension 137 (60.4) 33 (55.9) 104 (61.9) 0.442
Hypercholesterolemia 88 (38.8) 20 (33.9) 68 (40.5) 0.438
Diabetes mellitus 25 (11.0) 10 (16.9) 15 (8.9) 0.096
Smoking 47 (20.7) 15 (25.4) 32 (19.0) 0.351
Menopause 180 (87.8) 46 (85.1) 134 (88.7) 0.477
Coronary artery disease 19 (8.4) 4 (6.8) 15 (8.9) 0.787
Active cancer* 16 (8.0) 6 (11.3) 10 (6.8) 0.376
Chronic obstructive pulmonary disease* 19 (9.5) 6 (11.3) 13 (8.9) 0.593
Presenting features
Chest pain 161 (70.9) 27 (45.8) 134 (79.8) <0.001
Chest pain and dyspnea 30 (13.2) 15 (25.4) 15 (8.9) 0.003
Dyspnea 26 (11.5) 11 (18.6) 15 (8.9) 0.057
Continued on the next page
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122after the addition of further variables was considered
the incremental prognostic value. Statistical analysis
was performed using SPSS version 20.0 statistical
software (SPSS Inc., Chicago, Illinois).
RESULTS
Demographic and clinical characteristics. The study
population included 227 patients (66.2  12.2 years
of age; females, 90.3%). Demographic, clinical, and
ECG characteristics of the overall population are
shown in Table 1.
Patients with and without major adverse events
were compared. There was a striking prevalence of
females (91.5% vs. 89.9%, respectively; p ¼ 0.80) in
menopause (85.1% vs. 88.7%, respectively; p¼ 0.47)
in both groups. A signiﬁcantly higher proportion
of elderly patients $75 years of age (42.4% vs.
23.8%, respectively; p ¼ 0.011) was observed be-
tween those with major adverse events. Chest pain
with dyspnea (25.4% vs. 8.9%, respectively;
p ¼ 0.003) and increased heart rate (88.8  20.5
beats/min vs. 83.4  14.1 beats/min, respectively;
p ¼ 0.031) were signiﬁcantly more frequent among
patients with major adverse events. No signiﬁcant
differences were found between groups in ECG
presentation, LVmorphology, prevalence of triggers,and common cardiovascular risk factors. Conversely,
the involvement of$4 coronary territories was more
frequent (89%) and prevalent in patients with he-
modynamic instability (57 [96.6%] vs. 147 [87.5%]
patients, respectively; p¼ 0.047). Length of hospital
stay was signiﬁcantly longer in patients with major
adverse events (9 [5.0 to 12.2] vs. 6 [5 to 9] days,
respectively; p ¼ 0.002].
Major adverse events: acute heart failure, cardiogenic
shock, and in-hospital mortality. Overall complica-
tions are listed in Table 2. Acute heart failure was the
most common major complication (n ¼ 45; 19.6%).
Among the patients with acute heart failure, 5 pa-
tients had cardiogenic shock, 1 patient had cardio-
genic shock and stroke, 3 patients had ventricular
tachycardia/ﬁbrillation, 1 patient had ventricular
tachycardia/ﬁbrillation and atrial ﬁbrillation, 2 pa-
tients had atrial ﬁbrillation alone, and 1 patient had
apical thrombosis. Among patients with cardio-
genic shock (n ¼ 18; 7.8%), 3 had active cancer, 1
had stroke and preexisting atrial ﬁbrillation, and
another one had new-onset atrial ﬁbrillation.
Thirteen patients with cardiogenic shock (5.7%)
were treated with positive inotropic drugs or vaso-
pressors or both (dobutamine at an infusion rate of
2 to 20 mg/kg/min; norepinephrine at an infusion
rate of 0.2 to 1.0 mg/kg/min; or levosimendan at an
Table 1. Continued
Overall
Population
(n [ 227)
Patients With
Major
Complications
(n [ 59)
Patients Without
Major
Complications
(n [ 168) p Value
Other symptoms 10 (4.4) 6 (10.2) 4 (2.4) 0.021
Systolic blood pressure, mm Hg 131.1  25.6 129.6  32.6 131.6  23.1 0.606
Diastolic blood pressure, mm Hg 77.4  12.8 76.7  14.1 77.7 12.4 0.619
Heart rate, beats/min 84.8  16.1 88.8  20.5 83.4  14.1 0.031
Presence of identiﬁable trigger events 187 (82.4) 48 (81.4) 139 (82.7) 0.843
Emotional trigger 133 (58.6) 31 (52.5) 102 (60.7) 0.286
Physical trigger 54 (23.8) 17 (28.8) 37 (22.0) 0.190
Serum assays
Troponin I, ng/ml 0.9 (0.3–2.0) 0.7 (0.3–1.6) 0.9 (0.3–2.2) 0.691
CK-MB, ng/ml 19.7 (8.2–35) 18.5 (8.1–31) 20 (8.2–37.9) 0.401
BNP, pg/mly 806.8  181.3 856.0  207.0 790.0  169.4 0.047
Hemoglobin, g/dl 12.9  1.5 12.8  1.5 12.9  1.5 0.596
GFR, ml/min 70.2  21.5 66.4  25.2 71.6  19.5 0.118
CRP, mg/dl 12.6 (6.5–26.4) 13 (6.1–27.5) 12.5 (6.5–26.2) 0.938
ECG features at admission
Isolated STE 72 (31.7) 15 (25.4) 57 (33.9) 0.258
STE with TWI 72 (31.7) 21 (35.6) 51 (30.4) 0.516
Non-STE 53 (23.3) 15 (25.4) 38 (22.6) 0.721
Isolated TWI 30 (13.2) 8 (13.6) 22 (13.1) 1.000
Prolonged QTc-interval 99 (43.6) 23 (39.0) 76 (45.2) 0.447
Left ventricular morphology
Apical ballooning 175 (77.1) 42 (71.2) 133 (79.2) 0.213
Midventricular ballooning 41 (18.1) 12 (20.3) 29 (17.3) 0.694
Basal ballooning 11 (4.8) 5 (8.5) 6 (3.6) 0.159
Involvement of $4 coronary territories 204 (89.9) 57 (96.6) 147 (87.5) 0.047
Length of hospitalization, days 7 (5–10) 9 (5–12.2) 6 (5–9) 0.002
Continuous normally distributed variables are mean  SD. Categorical variables are n (%). Continuous non-normally distributed variables are median (interquartile
range). *Data were available for 199 patients (53 with major complications). yData were available for 157 patients (40 with major complications).
BNP ¼ brain natriuretic peptide; CK-MB ¼ creatine kinase-MB; CRP ¼ C-reactive protein; ECG ¼ electrocardiography; GFR ¼ glomerular ﬁltration rate; STE ¼
ST-segment elevation; TWI ¼ T-wave inversion.
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123infusion rate of 0.1 mg/kg/min). Despite treatment,
3 patients died during intensive care unit stay. Intra-
aortic balloon pumping was used in 6 of 18 patients
with cardiogenic shock admitted to facilities where
implantation of the device could be performed.
Of note, 10 patients with cardiogenic shock had
reversible moderate to severe MR. Death occurred in
6 patients (2.6%). Cardiac death was related to
cardiogenic shock in 3 patients and to acute heart
failure in 1 patient. Noncardiac death was associated
with malignancy in the remaining 2 patients. Among
11 patients with ventricular tachycardia/ﬁbrillation,
only 1 had torsade de pointes, and 9 had prolonged
QTc intervals (p ¼ 0.012).Echocardiographic ﬁndings on admission. Patients
with major adverse events had signiﬁcantly higher
indexed LV end-diastolic volume (p ¼ 0.002) and
LV end-systolic volume (p < 0.001), lower EF
(p< 0.001), higher wall motion score index (WMSI)
(p< 0.001) and larger LA volumes (p< 0.001) than
patients without major adverse events (Table 3).
Regarding diastolic function, all mitral inﬂow-
derived parameters were signiﬁcantly different be-
tween groups, as follows: E peak velocity (p< 0.001),
E/A ratio (p < 0.001), E-wave deceleration time
(p ¼ 0.011), and e0 peak velocity (p ¼ 0.007). In the
overall population, LVOTO was detected in 29
patients (only 2 received inotropic agents) and was
Table 2. Overall Complications
Major complications
Acute heart failure 45 (19.6)
Cardiogenic shock 18 (7.8)
Cardiac death 4 (1.7)
Other cardiac events
Ventricular tachycardia/ﬁbrillation 11 (4.8)*
Stroke 3 (1.3)
Apical thrombosis 3 (1.3)
Supraventricular tachycardia 1 (0.4)
Atrial ﬁbrillation 15 (6.6)
Syncope 1 (0.4)
Values are n (%). *9 patients had prolonged QTc intervals (p ¼ 0.012).
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124more common in patients with major adverse events
(p ¼ 0.006). Reversible moderate to severe MR was
detected in 49 patients and was prevalent in patients
with major adverse events (49.1% vs. 11.9%,
respectively, p < 0.001). Acute heart failure andTable 3. Echocardiographic Findings on Admission
Overall
Population
(n [ 227)
LV end-diastolic volume, ml 91.9  22.7
LV end-systolic volume, ml 57.3  15.2
Indexed LV end-diastolic volume, ml/m2 53.8  14.3
Indexed LV end-systolic volume, ml/m2 33.3  9.1
Diastolic IV septal thickness, mm 12.1  3.0
LV ejection fraction, % 37.5  5.2
Wall motion score index 1.8  0.2
Left atrial volume, ml 43.7  8.2
E peak velocity, cm/s 75.2  18.0
A peak velocity, cm/s 72.6  21.1
E/A ratio 1.0 (0.7–1.3)
DTE, ms 202.0  55.9
e0 peak velocity, cm/s 7.0  2.3
E/e0 ratio 11.0  4.0
sPAP, mm Hg 40.3  10.4
TAPSE, mm 19.2  3.2
Right ventricular area change, % 38.7  7.1
Moderate to severe MR 49 (21.5)
LV outﬂow tract obstruction 29 (12.8)
Right ventricular involvement 33 (14.5)
Values are mean  SD, median (interquartile range), or n (%).
DTE¼mitral E-wave deceleration time; E/A¼mitral early diastolic velocity (E, cm/s)
averaged e0 velocity; IV ¼ interventricular; LV ¼ left ventricular; MR ¼mitral regurgita
systolic excursion.cardiogenic shock occurred in 28 of 49 patients
(57%). Patients with moderate to severe MR had
lower EF (median [IQR] ¼ 38% [31 to 40] vs. 40%
[36 to 42], respectively) than patients without sig-
niﬁcant MR. Apical ballooning (40 of 49 patients;
81%) was prevalent in this subgroup. Seventeen pa-
tients had concomitant LVOTO and systolic ante-
rior motion (34.6%). RV involvement (28.8% vs.
9.5%, respectively; p ¼ 0.001) was more frequent
among patients with major adverse events. Indexes of
LV ﬁlling pressure, such as E/e0 ratio (p< 0.001) and
sPAP (p < 0.001), were signiﬁcantly higher, sug-
gesting a more compromised hemodynamic status in
the group with major adverse events.
Echocardiographic ﬁndings at short-term follow-up.
At short-term follow-up, all echocardiographic
measures examined were not signiﬁcantly different
between groups, except for LA volume (p < 0.001),
E peak velocity (p ¼ 0.002), E/A ratio (p ¼ 0.001),
e0 peak velocity (p < 0.001), E/e0 ratio (p < 0.001),
and sPAP (p ¼ 0.027), which remained higher in pa-
tients who experiencedmajor adverse events (Table 4).Patients With
Major
Complications
(n [ 59)
Patients Without
Major
Complications
(n [ 168) p Value
97.3  22.6 89.7  22.5 0.051
63.3  15.7 54.8  14.3 0.001
60.3  13.5 51.3  13.8 0.002
39.1  9.2 31.0  8.1 <0.001
12.3  3.4 12.0  2.9 0.471
35.1  5.9 38.4  4.6 <0.001
1.9  0.2 1.7  0.2 <0.001
47.4  7.4 42.1  8.1 <0.001
83.8  20.0 71.7  15.9 <0.001
68.0  26.8 74.5  18.2 0.081
1.2 (0.7–1.9) 0.9 (0.7–1.2) <0.001
181.1  54.0 209.3  54.9 0.011
6.2  2.1 7.3  2.3 0.007
13.5  4.3 9.9  3.3 <0.001
47.4  12.3 38.0  9.2 <0.001
19.4  2.9 19.6  3.3 0.709
34.3  8.1 40.1  5.8 <0.001
29 (49.1) 20 (11.9) <0.001
14 (23.7) 15 (8.9) 0.006
17 (28.8) 16 (9.5) 0.001
and late diastolic velocity (A, cm/s) ratio; E/e0 ¼ ratio of mitral E peak velocity and
tion; sPAP ¼ pulmonary artery systolic pressure; TAPSE ¼ tricuspid annular plane
Table 4. Echocardiographic Findings at Short-Term Follow-Up
Overall
Population
(n [ 227)
Patients With
Major
Complications
(n [ 59)
Patients Without
Major
Complications
(n [ 168) p Value
LV end-diastolic volume, ml 86.2  22.3 89.7  23.7 84.8  21.7 0.229
LV end-systolic volume, ml 38.2  11.0 39.8  11.1 37.5  10.9 0.271
Indexed LV end-diastolic volume, ml/m2 49.9  13.3 53.0  16.9 48.7  11.7 0.145
Indexed LV end-systolic volume, ml/m2 21.8  6.1 23.5  6.4 21.3  5.9 0.108
LV ejection fraction, % 55.5  7.1 54.7  7.1 55.8  7.1 0.319
Wall motion score index 1.1 (1–1.3) 1.1 (1–1.3) 1.1 (1–1.3) 0.753
Left atrial volume, ml 41.5  7.9 45.1  7.1 40.0  7.7 <0.001
E peak velocity, cm/s 67.5  15.1 74.8  17.4 64.5  13.1 0.002
A peak velocity, cm/s 84.6  19.5 80.4  25.1 86.7  16.7 0.151
E/A ratio 0.7 (0.6–0.9) 0.8 (0.6–1.3) 0.7 (0.6–0.8) 0.001
DTE, ms 230 (190–254) 217 (175–252) 239 (196–261.2) 0.851
e0 peak velocity, cm/s 9.3  2.0 7.9  1.8 9.8  1.8 <0.001
E/e0 ratio 7.1  2.2 9.1  2.5 6.3  2.2 <0.001
sPAP, mm Hg 28.  7.1 30.8  7.3 28.  6.9 0.027
TAPSE, mm 21.1  2.8 21.8  2.3 20.  2.9 0.032
Right ventricular area change, % 41.4  3.8 40.4  4.0 41.8  3.7 0.032
Moderate to severe MR 10 (7.6) 5 (12.8) 5 (5.4) 0.162
LV outﬂow tract obstruction 3 (1.3) 0 (0.0) 3 (1.8) 0.570
Right ventricular involvement 2 (0.9) 1 (1.7) 1 (0.6) 0.453
Values are mean  SD, median (interquartile range), or n (%).
Abbreviations as in Table 3.
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125Independent clinical and echocardiographic correlates
of major adverse events. At univariate analysis, age
$75 years, heart rate, LVOTO, RV involvement,
chest pain with dyspnea, LVEF, E/e0 ratio, sPAP,Table 5. Hazard Ratio (95% CI) for Acute Heart Failure, Cardiogeni
Multivariate Models
Univariate Model
Wald Chi-Square p Value HR
Age $75 yrs 7.162 0.007 2.353 1
Heart rate 4.492 0.034 1.020 1
Chest pain with dyspnea 9.552 0.002 3.477 1
BNP 3.385 0.049 1.002 1
LVEF 15.398 <0.001 0.892 0
E/e0 ratio 23.345 <0.001 1.266 1
sPAP 23.549 <0.001 1.086 1
Moderate to severe MR 23.532 <0.001 5.916 2
RV involvement 11.957 0.001 3.845 1
LVOT obstruction 7.992 0.005 3.173 1
BNP ¼ brain natriuretic peptide; CI ¼ conﬁdence interval; HR ¼ hazard ratio; LVEF ¼
regurgitation; RV ¼ right ventricular; sPAP ¼ pulmonary artery systolic pressure.and presence of moderate to severe MR at admission
were signiﬁcantly associated with the occurrence of
major adverse events (Table 5). At multivariate
analysis, LVEF, E/e0 ratio, reversible moderate toc Shock, and In-Hospital Mortality in Univariate and
Multivariate Model
95% CI Wald Chi-Square p Value HR 95% CI
.257–4.403 4.270 0.039 2.818 1.055–7.529
.001–1.038
.578–7.664
.000–1.004
.842–0.944 18.400 <0.001 0.923 0.890–0.958
.150–1.393 6.410 0.011 1.131 1.028–1.244
.050–1.122
.885–12.133 5.049 0.025 3.254 1.163–9.109
.792–8.250
.425–7.067
left ventricular ejection fraction; LVOT ¼ left ventricular outﬂow tract; MR ¼mitral
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126severe MR and age $75 years were independent
correlates of the composite outcome (Table 5). When
considering only 2 of 3 components of the composite
outcome, that is, cardiogenic shock and death, heart
rate (HR: 1.028, 95% CI: 1.004 to 1.052, p¼ 0.022),
LVEF (HR: 0.872, 95% CI: 0.819 to 0.928, p <
0.001), and reversible moderate to severe MR
(HR: 4.498, 95% CI: 1.366 to 14.811, p ¼ 0.013)
were identiﬁed as independent predictors. The
Hosmer-Lemeshow statistic was not signiﬁcant (p ¼
0.45), indicating a good model ﬁt.
Incremental prognostic value of independent echo-
cardiographic correlates of major adverse events.
Sequential models for the prediction of major adverse
events were used to assess the incremental contribu-
tion of echocardiographic correlates of major adverse
events compared with clinical, ECG, and laboratory
ﬁndings. For major adverse events, the clinical
model (chi-square: 40.7, p < 0.001) was slightly but
not signiﬁcantly improved by the addition of ECG
(chi-square: 46.2, p ¼ 0.24) and laboratory data
(chi-square: 50.9, p ¼ 0.19), respectively. A major
and signiﬁcant improvement was obtained only by
the addition of echocardiographic ﬁndings (chi-
square: 88.7, p < 0.001) (Fig. 1).
D I SCUSS ION
This study addressed the role of echocardiography
compared with those of other clinical, ECG, and
laboratory measures routinely used in daily practice in
the early evaluation of patients with TTC. The main
ﬁndings can be summarized as follows: 1) in a largeFigure 1. Incremental Prognostic Value of Echocardiography
in Tako-Tsubo Cardiomyopathy
Incremental prognostic value of independent echocardiographic
correlates of major adverse events to clinical data, electrocardio-
graphic (ECG) changes at admission, laboratory ﬁndings as deter-
mined by the comparison of the global chi-square at each step.series of TTC patients, approximately 25% devel-
oped pulmonary edema or cardiogenic shock during
the acute phase; 2) several echocardiographic ﬁnd-
ings, such as LVEF, WMSI, E/e0 ratio, LVOTO,
sPAP, and RV involvement and reversible moderate
to severe MR, were associated with such adverse
events; and 3) LVEF, reversible moderate to severe
MR, E/e0 ratio, and age$75 years were independent
correlates of acute heart failure, cardiogenic shock,
and in-hospital mortality. In addition, the prevalence
of some peculiar echocardiographic ﬁndings previ-
ously reported in small cohorts of TTC patients
have been documented in larger series.
Clinical relevance of systolic and diastolic echocardio-
graphic parameters. Most patients with TTC are
usually paucisymptomatic and have a favorable
in-hospital course. However, adverse events due to
hemodynamic instability (e.g., acute heart failure or
cardiogenic shock) may occur in up to one-fourth of
patients, even during the ﬁrst hours after clinical onset.
In our study, higher WMSI and lower LVEF
were associated with pulmonary edema and
cardiogenic shock, conﬁrming the fact that marked
LV systolic dysfunction contributes to the devel-
opment of hemodynamic instability (7). Increased
sympathetic stimulation seems to play a central role
in the occurrence of systolic impairment related to
myocardial stunning in TTC patients, through a
variety of pathophysiological mechanisms, including
myocyte calcium overload, oxidative stress, and
microvascular dysfunction (4,19,20). Lower peak
levels of cardiac enzymes are observed in TTC than
in acute coronary syndrome, despite more pro-
nounced myocardial dysfunction. The slight eleva-
tion of troponin and CK-MB levels seems to be
associated with myocardial stunning rather than
necrosis, as abnormal troponin levels do not neces-
sarily indicate true myocardial damage. The poten-
tial role of ECG abnormalities in predicting adverse
events in TTC has been previously investigated
(21). In the study by Takashio et al. (21), the
magnitude and extent of ST-segment elevation with
ECG were found to be independent predictors of
in-hospital adverse events. However, those ﬁndings
were not conﬁrmed by other authors (22). Although
ST-segment elevation is the most common ECG
presentation, it is detected in roughly 50% of pa-
tients, especially in Western countries (23). In
clinical practice, a marked disproportion between
troponin peak levels and the magnitude of ECG
changes compared with the extent of regional
myocardial dysfunction is frequently observed. Our
results demonstrate that LVEF is an independent
correlate of acute heart failure and is superior to
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127troponin and ECG in identifying patients at risk of
hemodynamic instability. Echocardiography seems
to better mirror the amount of dysfunctioning
myocardium than ECG alterations and serum pa-
rameters, conﬁrming the importance of multi-
parametric LV assessment in TTC patients.
TTC patients may show volume and pressure
overload secondary not only to acute systolic but also
to diastolic dysfunction. Interestingly, advanced age
and female sex that typically prevail in TTC were
found to be associated with LV diastolic stiffening
coupled with a stiff vascular system and endothelial
dysfunction (24). Basal hyperkinesis and apical LV
wall stress induce intraventricular diastolic and sys-
tolic pressure gradients and are believed to be the
primary mechanisms responsible for increased LV
ﬁlling pressure in this peculiar cardiomyopathy. In
TTC patients, elevated BNP levels were shown to
correlate with the severity of LV diastolic dysfunction
independent of troponin peak levels (25). In our study
as well as in other series, E/e0 ratio was elevated (26).
A relationship between decreased LV untwisting
(a regional diastolic index) and increased E/e0 ratio
(a global diastolic index) has been reported, de-
monstrating that diastolic function is impaired even
in the early phase of TTC (27). E/e0 ratio is consid-
ered a good predictor of LV ﬁlling pressure, and it
has already been proven useful in predicting outcome
in different cardiovascular diseases, also showing an
incremental prognostic value compared to BNP (28).
Our study demonstrates for the ﬁrst time that E/e0
ratio is a strong determinant of acute heart failure
and in-hospital mortality in patients with TTC. This
parameter should therefore be assessed early and
systematically in order to identify patients at higher
risk of hemodynamic instability and to guide appro-
priate management. In addition, the improvement in
E/e0 ratio and LV systolic function at follow-up may
be considered a useful indicator of LV function
recovery. Heart failure can also be precipitated by
elevated pulmonary artery pressure, usually related to
reduced LA compliance (advanced LV diastolic
dysfunction in elderly patients) or LA volume over-
load (signiﬁcant MR) (28). Of note, in our study, the
echocardiographic parameters of both systolic and
diastolic function, including E/e0 ratio, were signiﬁ-
cantly more compromised in patients with adverse
events than in those without. At short-term assess-
ment, despite comparable recovery of systolic func-
tion, some parameters of diastolic function (namely,
E/A ratio, E/e0 ratio, and LA volume) remained
signiﬁcantly outside of the normal range in patients
who experienced adverse events. As a possible
explanation for this ﬁnding, it may be hypothesizedthat pre-existing diastolic dysfunction may have been
unmasked following the resolution of the acute
phase, suggesting that TTC patients with impaired
diastolic function are more prone to develop acute
heart failure.
Reversible mitral regurgitation, acute heart failure,
and cardiogenic shock. Several aspects regarding the
impact of reversible signiﬁcant MR on the clinical
picture of TTC patients are still debated. First, the
true incidence remains to be clearly deﬁned. In our
study population, reversible signiﬁcant (moderate to
severe) MR during the acute phase was observed in
21% of TTC patients. This ﬁnding is consistent with
the prevalence (range 19% to 25%) reported in the
literature (29–31). Second, the cause of acute MR
remains to be fully elucidated. Two distinct under-
lying mechanisms seem to be associated with the
development of MR in TTC: 1) the coexistence of
systolic anterior motion and LVOTO; and 2) teth-
ering of the mitral valve leaﬂets (31). In our study,
only a minority of patients with signiﬁcant MR
showed concomitant LVOTO and systolic anterior
motion (7%), conﬁrming the hypothesis that
different underlying mechanisms may induce dy-
namic functional MR. Finally, equivocal data for the
association of MR with ballooning pattern, systolic
function, and prognosis have been reported so far. In
our study, patients with signiﬁcant MR had a
striking prevalence of apical ballooning pattern and,
if compared with patients without MR, had a lower
EF. These ﬁndings lead us to hypothesize that sig-
niﬁcant MR may be associated with more extensive
myocardial dysfunction. It is unquestionable that in a
context of stunning myocardium typical of TTC, the
left ventricle can compensate for the development of
an acute MR by increasing preload and emptying, as
expected in a normal ventricle (32). LV volume
overload results in increased myocardial tension that,
in a vicious circle, leads to systolic dysfunction and
reduced stroke volume (33). Ejection of the regur-
gitant volume into the left atrium before aortic valve
opening further reduces forward effective cardiac
output, predisposing to cardiogenic shock. In addi-
tion, LA pressure rises abruptly, especially in the
presence of normal or reduced LA compliance, often
leading to pulmonary congestion and acute heart
failure. In our study, 18 patients developed cardio-
genic shock and among these 10 (55%) had mod-
erate to severe MR. The prevalence of cardiogenic
shock in TTC was 15% in the study by Tsuchuhashi
et al. (1), but even rarer in other series (34). Song
et al. (35) reported the occurrence of cardiogenic
shock in 16 of 50 (32%) TTC patients. Patients
with cardiogenic shock had a signiﬁcantly higher
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128prevalence of reversible MR and apical ballooning
pattern than patients without cardiogenic shock. Our
data are consistent with those of Song et al. (35),
demonstrating that reversible moderate to severe
MR is an independent determinant of major adverse
events. In addition, reversible MR remained a sig-
niﬁcant independent correlate even after considering
cardiogenic shock and death as the only components
of the composite outcome. Owing to its potential
negative impact on in-hospital course, early echo-
cardiographic assessment of the mitral valve should
be performed, with special attention to hemody-
namics in moderate to severe MR, in particular in
patients with advanced systolic dysfunction and
LVOTO.
LVOTO has been reported in 25% of patients in
a small series of 32 TTC patients (17). In our
larger population, the prevalence of LVOTO was
12.8%. LVOTO should be systematically ruled out
by echocardiography in order to implement an
appropriate therapeutic strategy. In patients with
LVOTO and markedly impaired LV systolic func-
tion, ß-blockade and intra-aortic balloon counter-
pulsation should be the preferred treatment options
compared to inotropic agents to prevent the devel-
opment of signiﬁcant intraventricular gradients and
subsequent hemodynamic deterioration (36).
Study limitations. Several issues should be consid-
ered when interpreting these data. First, only pa-
tients with good acoustic windows were evaluated.
Although our intraobserver and interobserver vari-
ability in evaluating LVwall motion contraction were
good (9), visual assessment of wall motion may have
been affected by the tethering phenomenon. Second,
catecholamine levels were not reported. However,
our observation reﬂects clinical practice in a real-
world setting, where measurement of catechol-
amine levels is not systematically performed in the
acute phase of TTC. In addition, to date, the link
among sympathetic activation, elevated circulating
catecholamines, and the occurrence of stunnedmyocardium in TTC remains hypothetical (37). It
would have been of interest to compare the associa-
tion of echocardiographic and cardiac magnetic
resonance (CMR) parameters in TTC patients with
and without complications. In a prospective study,
Eitel et al. (38) reported robust data for CMR in
a large cohort of TTC patients enrolled from 7 ter-
tiary care centers in Europe and North America.
However, their series included only 1 patient with
cardiogenic shock, probably because CMR is difﬁ-
cult to perform in patients with hemodynamic
instability. Finally, CMR is not largely available and
not systematically used, especially in the early eval-
uation of patients with acute coronary syndrome or
similar conditions.
CONCLUS IONS
Echocardiographic parameters provide additional
information compared to other variables routinely
used in clinical practice in identifying patients at
higher risk of hemodynamic deterioration and poor
in-hospital outcome. Our study demonstrates for the
ﬁrst time that LVEF, reversible moderate to severe
MR, E/e0 ratio, and age $75 years are independent
correlates of major adverse events (i.e., acute heart
failure, cardiogenic shock, and in-hospital mortality)
in a large cohort of TTC patients. Comprehensive
seriated echocardiographic examinations should be
systematically performed in patients with TTC to
monitor systolic and diastolic LV function recovery.
Special attention should be paid to patients with
signiﬁcant MR and intraventricular obstruction to
promptly institute appropriate pharmacological
treatment and adequate mechanical support.
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